www.zentaris.com Open in urlscan Pro
34.149.87.45  Public Scan

Form analysis
0 forms found in the DOM

Text Content

top of page
Skip to Main Content


 * About
   
   * About
   * Leadership Team
   * Board of Directors
   * Locations

 * Our Product
   
   * Macimorelin DX
   * Publications

 * Our Pipeline
   
   * Overview
   * AIM Biologicals
   * AEZS-150
   * AEZS-130 (Macimorelin)
   * Macimorelin Dx
   * Publications

 * Clinical Studies

 * News

 * Investors
   
   * Overview
   * Press Releases
   * Events
   * Analyst Coverage
   * Company Information
   * Stock Data
   * Financial Filings
   * Corporate Governance
   * Board Committees
   * Board Diversity Matrix
   * Governance Documents
   * Executive Compensation Clawback Policy
   * Annual Reports
   * AGM Court Materials
   * Email Alerts

 * Contact

 * More...


Use tab to navigate through the menu items.
 * 
 * 
 * 


PIPELINE        AIM BIOLOGICALS         AEZS-150        AEZS-130 (MACIMORELIN) 
      MACIMORELIN DX         




THERAPEUTIC DEVELOPMENT PIPELINE




DIAGNOSTIC PIPELINE








Sales of Macrilen® (macimorelin) are temporarily discontinued in the United
States commercial market for the diagnosis of adult growth hormone deficiency
("AGHD"), until anticipated re-launch with an alternate commercialization
partner. Aeterna has an ongoing effort to identify strategic development and
commercialization partner.

+ MORE


LATEST NEWS



+ MORE

Specialty Biopharmaceutical Company


STOCK INFO


+ INVESTORS




Data delayed 15 minutes unless otherwise indicated

CORPORATE PRESENTATION



+ SIGN UP FOR ALERTS

STAY UP TO DATE ON NEWS, FILINGS AND EVENTS



©2024 AETERNA ZENTARIS  ALL RIGHTS RESERVED.

TERMS AND CONDITIONS    PRIVACY POLICY

CONTACT US

 * 
 * 
 * 

Our Use of Cookies

We use cookies that are strictly necessary to make our site work. Cookies are
used for the purposes of improving site content and measuring site usage. By
clicking "Accept and Continue" you are agreeing to the use of these cookies. For
more information on our use of cookies, please visit our Privacy page.

Accept and Continue
bottom of page